Search for antiviral functions of potentially protective antibodies against V2 region of HIV-1

References

• Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, Premsri N, Namwat C, de Souza M, Adams E, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med. 2009;361:2209–20. doi:10.1056/NEJMoa0908492.
   PubMed Web of Science ®Google Scholar
• Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, Evans DT, Montefiori DC, Karnasuta C, Sutthent R, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med. 2012;366:1275–86. doi:10.1056/NEJMoa1113425.
   PubMed Web of Science ®Google Scholar
• He Y, Honnen WJ, Krachmarov CP, Burkhart M, Kayman SC, Corvalan J, Pinter A. Efficient isolation of novel human monoclonal antibodies with neutralizing activity against HIV-1 from transgenic mice expressing human Ig loci. J Immunol. 2002;169:595–605. doi:10.4049/jimmunol.169.1.595.
   PubMed Web of Science ®Google Scholar
• Liu L, Li L, Nanfack A, Mayr LM, Soni S, Kohutnicki A, Agyingi L, Wang XH, Tuen M, Shao Y, et al. Anti-V2 antibody deficiency in individuals infected with HIV-1 in Cameroon. Virology. 2019;529:57–64. doi:10.1016/j.virol.2019.01.011.
   PubMed Web of Science ®Google Scholar
• Zolla-Pazner S, deCamp A, Gilbert PB, Williams C, Yates NL, Williams WT, Howington R, Fong Y, Morris DE, Soderberg KA, et al. Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection. PLoS One. 2014;9:e87572. doi:10.1371/journal.pone.0087572.
   PubMed Web of Science ®Google Scholar
• Gottardo R, Bailer RT, Korber BT, Gnanakaran S, Phillips J, Shen X, Tomaras GD, Turk E, Imholte G, Eckler L, et al. Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial. PLoS One. 2013;8:e75665. doi:10.1371/journal.pone.0075665.
   PubMed Web of Science ®Google Scholar
• Di Mascio M, Lifson JD, Srinivasula S, Kim I, DeGrange P, Keele BF, Belli AJ, Reimann KA, Wang Y, Proschan M, et al. Evaluation of an antibody to alpha4beta7 in the control of SIVmac239-nef-stop infection. Science. 2019;365:1025–29. doi:10.1126/science.aav6695.
   PubMed Web of Science ®Google Scholar
• Abbink P, Mercado NB, Nkolola JP, Peterson RL, Tuyishime H, McMahan K, Moseley ET, Borducchi EN, Chandrashekar A, Bondzie EA, et al. Lack of therapeutic efficacy of an antibody to alpha4beta7 in SIVmac251-infected rhesus macaques. Science. 2019;365:1029–33. doi:10.1126/science.aaw8562.
   PubMed Web of Science ®Google Scholar
• Iwamoto N, Mason RD, Song K, Gorman J, Welles HC, Arthos J, Cicala C, Min S, King HAD, Belli AJ, et al. Blocking alpha4beta7 integrin binding to SIV does not improve virologic control. Science. 2019;365:1033–36. doi:10.1126/science.aaw7765.
   PubMedGoogle Scholar
• Sneller MC, Clarridge KE, Seamon C, Shi V, Zorawski MD, Justement JS, Blazkova J, Huiting ED, Proschan MA, Mora JR, et al. An open-label phase 1 clinical trial of the anti-alpha4beta7 monoclonal antibody vedolizumab in HIV-infected individuals. Sci Transl Med. 2019;11:eaax3447. doi:10.1126/scitranslmed.aax3447.
   PubMed Web of Science ®Google Scholar
• McLellan JS, Pancera M, Carrico C, Gorman J, Julien JP, Khayat R, Louder R, Pejchal R, Sastry M, Dai K, et al. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature. 2011;480:336–43. doi:10.1038/nature10696.
   PubMed Web of Science ®Google Scholar
• de Taeye SW, Go EP, Sliepen K, de la Pena AT, Badal K, Medina-Ramirez M, Lee WH, Desaire H, Wilson IA, Moore JP, et al. Stabilization of the V2 loop improves the presentation of V2 loop-associated broadly neutralizing antibody epitopes on HIV-1 envelope trimers. J Biol Chem. 2019;294:5616–31. doi:10.1074/jbc.RA118.005396.
   PubMed Web of Science ®Google Scholar
• Shen X, Duffy R, Howington R, Cope A, Sadagopal S, Park H, Pal R, Kwa S, Ding S, Yang OO, et al. Vaccine-induced linear epitope-specific antibodies to Simian immunodeficiency virus SIVmac239 envelope are distinct from those induced to the human immunodeficiency virus type 1 envelope in nonhuman primates. J Virol. 2015;89:8643–50. doi:10.1128/JVI.03635-14.
   PubMed Web of Science ®Google Scholar
• Jiang X, Totrov M, Li W, Sampson JM, Williams C, Lu H, Wu X, Lu S, Wang S, Zolla-Pazner S, et al. Rationally designed immunogens targeting HIV-1 gp120 v1v2 induce distinct conformation-specific antibody responses in rabbits. J Virol. 2016;90:11007–19. doi:10.1128/JVI.01409-16.
   PubMed Web of Science ®Google Scholar
• Zolla-Pazner S, deCamp AC, Cardozo T, Karasavvas N, Gottardo R, Williams C, Morris DE, Tomaras G, Rao M, Billings E, et al. Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trial. PLoS One. 2013;8:e53629. doi:10.1371/journal.pone.0053629.
   PubMed Web of Science ®Google Scholar
• Karasavvas N, Billings E, Rao M, Williams C, Zolla-Pazner S, Bailer RT, Koup RA, Madnote S, Arworn D, Shen X, et al. The Thai Phase III HIV Type 1 vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120. AIDS Res Hum Retroviruses. 2012;28:1444–57. doi:10.1089/aid.2012.0103.
   PubMed Web of Science ®Google Scholar
• Gray GE, Huang Y, Grunenberg N, Laher F, Roux S, Andersen-Nissen E, De Rosa SC, Flach B, Randhawa AK, Jensen R, et al. Immune correlates of the Thai RV144 HIV vaccine regimen in South Africa. Sci Transl Med. 2019;11:eaax1880. doi:10.1126/scitranslmed.aax1880.
   PubMed Web of Science ®Google Scholar
• Laman JD, Claassen E, Noelle RJ. Functions of CD40 and Its Ligand, gp39 (CD40L). Crit Rev Immunol. 2017;37:371–420. doi:10.1615/CritRevImmunol.v37.i2-6.100.
   PubMed Web of Science ®Google Scholar
• Rouphael NG, Morgan C, SS L, Jensen R, Sanchez B, Karuna S, Swann E, Sobieszczyk ME, Frank I, Wilson GJ, et al., Team HP, the NHIVVTN. DNA priming and gp120 boosting induces HIV-specific antibodies in a randomized clinical trial. J Clin Invest. 2019;129:4769–85. doi:10.1172/JCI128699.
   PubMed Web of Science ®Google Scholar
• Barouch DH, Stephenson KE, Borducchi EN, Smith K, Stanley K, McNally AG, Liu J, Abbink P, Maxfield LF, Seaman MS, et al. Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys. Cell. 2013;155:531–39. doi:10.1016/j.cell.2013.09.061.
   PubMed Web of Science ®Google Scholar
• Barouch DH, Tomaka FL, Wegmann F, Stieh DJ, Alter G, Robb ML, Michael NL, Peter L, Nkolola JP, Borducchi EN, et al. Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19). Lancet. 2018;392:232–43. doi:10.1016/S0140-6736(18)31364-3.
   PubMed Web of Science ®Google Scholar
• Bradley T, Pollara J, Santra S, Vandergrift N, Pittala S, Bailey-Kellogg C, Shen X, Parks R, Goodman D, Eaton A, et al. Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge. Nat Commun. 2017;8:15711. doi:10.1038/ncomms15711.
   PubMed Web of Science ®Google Scholar
• Barouch DH, Liu J, Li H, Maxfield LF, Abbink P, Lynch DM, Iampietro MJ, SanMiguel A, Seaman MS, Ferrari G, et al. Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature. 2012;482:89–93. doi:10.1038/nature10766.
   PubMed Web of Science ®Google Scholar
• Roederer M, Keele BF, Schmidt SD, Mason RD, Welles HC, Fischer W, Labranche C, Foulds KE, Louder MK, Yang ZY, et al. Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIV. Nature. 2014;505:502–08. doi:10.1038/nature12893.
   PubMed Web of Science ®Google Scholar
• Singh S, Ramirez-Salazar EG, Doueiri R, Valentin A, Rosati M, Hu X, Keele BF, Shen X, Tomaras GD, Ferrari G, et al. Control of heterologous Simian immunodeficiency virus SIVsmE660 infection by DNA and protein coimmunization regimens combined with different toll-like-receptor-4-based adjuvants in Macaques. J Virol. 2018;92:e00281–18. doi:10.1128/JVI.00281-18.
   PubMed Web of Science ®Google Scholar
• Kwa S, Sadagopal S, Shen X, Hong JJ, Gangadhara S, Basu R, Victor B, Iyer SS, LaBranche CC, Montefiori DC, et al. CD40L-adjuvanted DNA/modified vaccinia virus Ankara simian immunodeficiency virus (SIV) vaccine enhances protection against neutralization-resistant mucosal SIV infection. J Virol. 2015;89:4690–95. doi:10.1128/JVI.03527-14.
   PubMed Web of Science ®Google Scholar
• Nyambi PN, Mbah HA, Burda S, Williams C, Gorny MK, Nadas A, Zolla-Pazner S. Conserved and exposed epitopes on intact, native, primary human immunodeficiency virus type 1 virions of group M. J Virol. 2000;74:7096–107. doi:10.1128/JVI.74.15.7096-7107.2000.
   PubMed Web of Science ®Google Scholar
• Liu P, Yates NL, Shen X, Bonsignori M, Moody MA, Liao HX, Fong Y, Alam SM, Overman RG, Denny T, et al. Infectious virion capture by HIV-1 gp120-specific IgG from RV144 vaccinees. J Virol. 2013;87:7828–36. doi:10.1128/JVI.02737-12.
   PubMed Web of Science ®Google Scholar
• Gorny MK, Moore JP, Conley AJ, Karwowska S, Sodroski J, Williams C, Burda S, Boots LJ, Zolla-Pazner S. Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1. J Virol. 1994;68:8312–20. doi:10.1128/JVI.68.12.8312-8320.1994.
   PubMed Web of Science ®Google Scholar
• Gorny MK, Pan R, Williams C, Wang XH, Volsky B, O’Neal T, Spurrier B, Sampson JM, Li L, Seaman MS, et al. Functional and immunochemical cross-reactivity of V2-specific monoclonal antibodies from HIV-1-infected individuals. Virology. 2012;427:198–207. doi:10.1016/j.virol.2012.02.003.
   PubMed Web of Science ®Google Scholar
• Corti D, Langedijk JP, Hinz A, Seaman MS, Vanzetta F, Fernandez-Rodriguez BM, Silacci C, Pinna D, Jarrossay D, Balla-Jhagjhoorsingh S, et al. Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS One. 2010;5:e8805. doi:10.1371/journal.pone.0008805.
   PubMed Web of Science ®Google Scholar
• Liao HX, Bonsignori M, Alam SM, McLellan JS, Tomaras GD, Moody MA, Kozink DM, Hwang KK, Chen X, Tsao CY, et al. Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. Immunity. 2013;38:176–86. doi:10.1016/j.immuni.2012.11.011.
   PubMed Web of Science ®Google Scholar
• Li L, Wang XH, Williams C, Volsky B, Steczko O, Seaman MS, Luthra K, Nyambi P, Nadas A, Giudicelli V, et al. A broad range of mutations in HIV-1 neutralizing human monoclonal antibodies specific for V2, V3, and the CD4 binding site. Mol Immunol. 2015;66:364–74. doi:10.1016/j.molimm.2015.04.011.
   PubMed Web of Science ®Google Scholar
• Montefiori DC, Karnasuta C, Huang Y, Ahmed H, Gilbert P, de Souza MS, McLinden R, Tovanabutra S, Laurence-Chenine A, Sanders-Buell E, et al. Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. J Infect Dis. 2012;206:431–41. doi:10.1093/infdis/jis367.
   PubMed Web of Science ®Google Scholar
• Alam SM, Liao HX, Tomaras GD, Bonsignori M, Tsao CY, Hwang KK, Chen H, Lloyd KE, Bowman C, Sutherland L, et al. Antigenicity and immunogenicity of RV144 vaccine AIDSVAX clade E envelope immunogen is enhanced by a gp120 N-terminal deletion. J Virol. 2013;87:1554–68. doi:10.1128/JVI.00718-12.
   PubMed Web of Science ®Google Scholar
• Hessell AJ, Powell R, Jiang X, Luo C, Weiss S, Dussupt V, Itri V, Fox A, Shapiro MB, Pandey S, et al. Multimeric epitope-scaffold HIV vaccines target V1V2 and differentially tune polyfunctional antibody responses. Cell Rep. 2019;28:877–895 e6. doi:10.1016/j.celrep.2019.06.074.
   PubMed Web of Science ®Google Scholar
• Davis KL, Gray ES, Moore PL, Decker JM, Salomon A, Montefiori DC, Graham BS, Keefer MC, Pinter A, Morris L, et al. High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination. Virology. 2009;387:414–26. doi:10.1016/j.virol.2009.02.022.
   PubMed Web of Science ®Google Scholar
• Escolano A, Gristick HB, Abernathy ME, Merkenschlager J, Gautam R, Oliveira TY, Pai J, West AP Jr., Barnes CO, Cohen AA, et al. Immunization expands B cells specific to HIV-1 V3 glycan in mice and macaques. Nature. 2019;570:468–73. doi:10.1038/s41586-019-1250-z.
   PubMed Web of Science ®Google Scholar
• Saunders KO, Wiehe K, Tian M, Acharya P, Bradley T, Alam SM, Go EP, Scearce R, Sutherland L, Henderson R, et al. Targeted selection of HIV-specific antibody mutations by engineering B cell maturation. Science. 2019;366:eaay7199. doi:10.1126/science.aay7199.
   PubMed Web of Science ®Google Scholar
• Steichen JM, Lin YC, Havenar-Daughton C, Pecetta S, Ozorowski G, Willis JR, Toy L, Sok D, Liguori A, Kratochvil S, et al. A generalized HIV vaccine design strategy for priming of broadly neutralizing antibody responses. Science. 2019;366:eaax4380. doi:10.1126/science.aax4380.
   PubMed Web of Science ®Google Scholar
• Hessell AJ, Shapiro MB, Powell R, Malherbe DC, McBurney SP, Pandey S, Cheever T, Sutton WF, Kahl C, Park B, et al. Reduced cell-associated DNA and improved viral control in Macaques following passive transfer of a single anti-V2 monoclonal antibody and repeated simian/human immunodeficiency virus challenges. J Virol. 2018;92:e02198–17. doi:10.1128/JVI.02198-17.
   PubMed Web of Science ®Google Scholar
• Moog C, Dereuddre-Bosquet N, Teillaud JL, Biedma ME, Holl V, Van Ham G, Heyndrickx L, Van Dorsselaer A, Katinger D, Vcelar B, et al. Protective effect of vaginal application of neutralizing and nonneutralizing inhibitory antibodies against vaginal SHIV challenge in macaques. Mucosal Immunol. 2014;7:46–56. doi:10.1038/mi.2013.23.
   PubMed Web of Science ®Google Scholar
• Burton DR, Hessell AJ, Keele BF, Klasse PJ, Ketas TA, Moldt B, Dunlop DC, Poignard P, Doyle LA, Cavacini L, et al. Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody. Proc Natl Acad Sci U S A. 2011;108:11181–86. doi:10.1073/pnas.1103012108.
   PubMed Web of Science ®Google Scholar
• Santra S, Tomaras GD, Warrier R, Nicely NI, Liao HX, Pollara J, Liu P, Alam SM, Zhang R, Cocklin SL, et al. Human non-neutralizing HIV-1 envelope monoclonal antibodies limit the number of founder viruses during SHIV mucosal infection in rhesus Macaques. PLoS Pathog. 2015;11:e1005042. doi:10.1371/journal.ppat.1005042.
   PubMed Web of Science ®Google Scholar
• Igarashi T, Brown C, Azadegan A, Haigwood N, Dimitrov D, Martin MA, Shibata R. Human immunodeficiency virus type 1 neutralizing antibodies accelerate clearance of cell-free virions from blood plasma. Nat Med. 1999;5:211–16. doi:10.1038/5576.
   PubMed Web of Science ®Google Scholar
• Mayr LM, Decoville T, Schmidt S, Laumond G, Klingler J, Ducloy C, Bahram S, Zolla-Pazner S, Moog C. Non-neutralizing antibodies targeting the V1V2 domain of HIV exhibit strong antibody-dependent cell-mediated cytotoxic activity. Sci Rep. 2017;7:12655. doi:10.1038/s41598-017-12883-6.
   PubMed Web of Science ®Google Scholar
• Musich T, Li L, Liu L, Zolla-Pazner S, Robert-Guroff M, Gorny MK. Monoclonal antibodies specific for the V2, V3, CD4-binding site, and gp41 of HIV-1 mediate phagocytosis in a dose-dependent manner. J Virol. 2017;91:e02325–16. doi:10.1128/JVI.02325-16.
   PubMed Web of Science ®Google Scholar
• Zolla-Pazner S, Powell R, Yahyaei S, Williams C, Jiang X, Li W, Lu S, Wang S, Upadhyay C, Hioe CE, et al. Rationally designed vaccines targeting the V2 region of HIV-1 gp120 induce a focused, cross-clade-reactive, biologically functional antibody response. J Virol. 2016;90:10993–1006. doi:10.1128/JVI.01403-16.
   PubMed Web of Science ®Google Scholar
• Duerr R, Gorny MK. V2-specific antibodies in HIV-1 vaccine research and natural infection: controllers or surrogate markers. Vaccines (Basel). 2019;7:E82. doi:10.3390/vaccines7030082.
   PubMed Web of Science ®Google Scholar
• Arthos J, Cicala C, Martinelli E, Macleod K, Van Ryk D, Wei D, Xiao Z, Veenstra TD, Conrad TP, Lempicki RA, et al. HIV-1 envelope protein binds to and signals through integrin alpha4beta7, the gut mucosal homing receptor for peripheral T cells. Nat Immunol. 2008;9:301–09. doi:10.1038/ni1566.
   PubMed Web of Science ®Google Scholar
• Nakamura GR, Fonseca DP, O’Rourke SM, Vollrath AL, Berman PW. Monoclonal antibodies to the V2 domain of MN-rgp120: fine mapping of epitopes and inhibition of alpha4beta7 binding. PLoS One. 2012;7:e39045. doi:10.1371/journal.pone.0039045.
   PubMed Web of Science ®Google Scholar
• Lertjuthaporn S, Cicala C, Van Ryk D, Liu M, Yolitz J, Wei D, Nawaz F, Doyle A, Horowitch B, Park C, et al. Select gp120 V2 domain specific antibodies derived from HIV and SIV infection and vaccination inhibit gp120 binding to alpha4beta7. PLoS Pathog. 2018;14:e1007278. doi:10.1371/journal.ppat.1007278.
   PubMed Web of Science ®Google Scholar
• Cicala C, Martinelli E, McNally JP, Goode DJ, Gopaul R, Hiatt J, Jelicic K, Kottilil S, Macleod K, O’Shea A, et al. The integrin alpha4beta7 forms a complex with cell-surface CD4 and defines a T-cell subset that is highly susceptible to infection by HIV-1. Proc Natl Acad Sci U S A. 2009;106:20877–82. doi:10.1073/pnas.0911796106.
   PubMed Web of Science ®Google Scholar
• Byrareddy SN, Arthos J, Cicala C, Villinger F, Ortiz KT, Little D, Sidell N, Kane MA, Yu J, Jones JW, et al. Sustained virologic control in SIV+ macaques after antiretroviral and alpha4beta7 antibody therapy. Science. 2016;354:197–202. doi:10.1126/science.aag1276.
   PubMed Web of Science ®Google Scholar
• Ling L, Wu T, To KKW, Cheung KW, Lui KOL, Niu M, Lam KS, Wang CC, Li J, Wang H, et al. Vedolizumab-mediated integrin alpha4beta7 blockade does not control HIV-1SF162 rebound after combination antiretroviral therapy interruption in humanized mice. AIDS. 2019;33:F1–F12. doi:10.1097/QAD.0000000000002149.
   PubMed Web of Science ®Google Scholar
• Rolland M, Edlefsen PT, Larsen BB, Tovanabutra S, Sanders-Buell E, Hertz T, deCamp AC, Carrico C, Menis S, Magaret CA, et al. Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. Nature. 2012;490:417–20. doi:10.1038/nature11519.
   PubMed Web of Science ®Google Scholar
• deCamp AC, Rolland M, Edlefsen PT, Sanders-Buell E, Hall B, Magaret CA, Fiore-Gartland AJ, Juraska M, Carpp LN, Karuna ST, et al. Sieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of Env-gp120. PLoS One. 2017;12:e0185959. doi:10.1371/journal.pone.0185959.
   PubMed Web of Science ®Google Scholar
• Malherbe DC, Mendy J, Vang L, Barnette PT, Reed J, Lakhashe SK, Owuor J, Gach JS, Legasse AW, Axthelm MK, et al. Combination adenovirus and protein vaccines prevent infection or reduce viral burden after heterologous clade c simian-human immunodeficiency virus mucosal challenge. J Virol. 2018;92:e01092–17. doi:10.1128/JVI.01092-17.
   PubMed Web of Science ®Google Scholar
• Pegu P, Vaccari M, Gordon S, Keele BF, Doster M, Guan Y, Ferrari G, Pal R, Ferrari MG, Whitney S, et al. Antibodies with high avidity to the gp120 envelope protein in protection from simian immunodeficiency virus SIV(mac251) acquisition in an immunization regimen that mimics the RV-144 Thai trial. J Virol. 2013;87:1708–19. doi:10.1128/JVI.02544-12.
   PubMed Web of Science ®Google Scholar
• Gordon SN, Doster MN, Kines RC, Keele BF, Brocca-Cofano E, Guan Y, Pegu P, Liyanage NP, Vaccari M, Cuburu N, et al. Antibody to the gp120 V1/V2 loops and CD4+ and CD8+ T cell responses in protection from SIVmac251 vaginal acquisition and persistent viremia. J Immunol. 2014;193:6172–83. doi:10.4049/jimmunol.1401504.
   PubMed Web of Science ®Google Scholar
• Gordon SN, Liyanage NP, Doster MN, Vaccari M, Vargas-Inchaustegui DA, Pegu P, Schifanella L, Shen X, Tomaras GD, Rao M, et al. Boosting of ALVAC-SIV vaccine-primed Macaques with the CD4-SIVgp120 fusion protein elicits antibodies to V2 associated with a decreased risk of SIVmac251 acquisition. J Immunol. 2016;197:2726–37. doi:10.4049/jimmunol.1600674.
   PubMed Web of Science ®Google Scholar
• Vaccari M, Gordon SN, Fourati S, Schifanella L, Liyanage NP, Cameron M, Keele BF, Shen X, Tomaras GD, Billings E, et al. Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition. Nat Med. 2016;22:762–70. doi:10.1038/nm.4105.
   PubMed Web of Science ®Google Scholar
• Vaccari M, Fourati S, Gordon SN, Brown DR, Bissa M, Schifanella L, Silva de Castro I, Doster MN, Galli V, Omsland M, et al. HIV vaccine candidate activation of hypoxia and the inflammasome in CD14(+) monocytes is associated with a decreased risk of SIVmac251 acquisition. Nat Med. 2018;24:847–56. doi:10.1038/s41591-018-0025-7.
   PubMed Web of Science ®Google Scholar
• Sui Y, Lewis GK, Wang Y, Berckmueller K, Frey B, Dzutsev A, Vargas-Inchaustegui D, Mohanram V, Musich T, Shen X, et al. Mucosal vaccine efficacy against intrarectal SHIV is independent of anti-Env antibody response. J Clin Invest. 2019;129:1314–28. doi:10.1172/JCI122110.
   PubMed Web of Science ®Google Scholar
• Su B, Dispinseri S, Iannone V, Zhang T, Wu H, Carapito R, Bahram S, Scarlatti G, Moog C. Update on Fc-mediated antibody functions against HIV-1 beyond neutralization. Front Immunol. 2019;10:2968. doi:10.3389/fimmu.2019.02968.
   PubMed Web of Science ®Google Scholar
• Bohl C, Bowder D, Thompson J, Abrahamyan L, Gonzalez-Ramirez S, Mao Y, Sodroski J, Wood C, Xiang SH. A twin-cysteine motif in the V2 region of gp120 is associated with SIV envelope trimer stabilization. PLoS One. 2013;8:e69406. doi:10.1371/journal.pone.0069406.
   PubMed Web of Science ®Google Scholar
• Hessell AJDM, Barnette P, Pandey S, Sutton W, Liu L, Li L, Kong X-P, Haigwood NL, Gorny MK. 2018. Tight control of viremia after SHIV BaL.P4 challenge in rhesus macaques immunized with HIV vaccine mimicking the RV144 regimen. Keystone Symposia, HIV Vaccines; 2018 January 28-February 2; Banff, Canada. Abstract.
   Google Scholar
• Hessell AJDM, Barnette P, Pandey S, Sutton W, Liu L, Li L, Kong X-P, Haigwood NL, Gorny MK. 2018. Tight control of SHIV BaL.P4 challenge in rhesus macaques co-immunized with DNA and protein HIV vaccine regimen. HIV Research for Prevention; 2018 Oct 21-25; Madrid, Spain. Abstract.
   Google Scholar
• Hessell AJDM, Barnette P, Pandey S, Sutton W, Li L, Tuen M, Gach JS, Forthal DN, Duerr R, Jiang X, et al. 2019. Tight control of SHIV challenge in macaques with vaccine-induced neutralizing and non-neutralizing anti-V2 antibodies. Keystone Symposia, HIV Vaccines; 2019 Mar 21-24; Whistler, Canada. Abstract.
   Google Scholar
• Li LDM, Barnette P, Pandey S, Sutton W, Spencer D, Gach JS, Hunegnaw R, Tuen M, Jiang X, Shao Y, et al.. 2019. Impact of vaccine-induced anti-V2 antibodies on virus control in SHIVBaL.P4 challenged rhesus macaques. International Society for Vaccines, Annual Congress; 2019 Oct 27-29; Ghent, Belgium. Abstract.
   Google Scholar